Skip to main content
Figure 1 | Trials

Figure 1

From: The role of extended-release niacin on immune activation and neurocognition in HIV-infected patients treated with antiretroviral therapy – CTN PT006: study protocol for a randomized controlled trial

Figure 1

Study design. Arm 1: ER niacin administration begins at week 0 and ends at week 24 (defined as ‘immediate use’ arm). Arm 2: ER niacin administration begins after the week 24 visit and ends at week 48 (defined as ‘deferred use’ arm). ART, Antiretroviral therapy; ER, extended-release.

Back to article page

Trials

ISSN: 1745-6215